The tumor of patient 2 revealed a high proportion of KRAS p.G12A mutated cells (64.2%), concordant with our previous results and reflecting an amplification of the mutant allele, but no NRAS mutation (tumor cell content of the whole section: 70%). This evidence concerns the gene KRAS and neoplasm.